Vortioxetine Hydrobromide

We have to go back to the 30 layoff rounds reported in the first quarter of 2022 to find a similarly low level during the first three months of the year.\n Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures.According to an analysis of Fierce Biotech’s layoff data, a total of 33 biopharma companies were reported to be either laying off employees or shutting down in the first three months of this year. While still high, this number is indicative of a gradual trend of slowing job cuts that Fierce first identified back in September. That downward trajectory resulted in a similar 33 layoff rounds in the final quarter of 2025, barely half of the 64 and 62 layoff announcements seen in the second and third quarters of last year, respectively.Last year was certainly tough, as demonstrated by a separate Fierce Pharma analysis that showed that the 17 pharma companies with at least $20 billion in annual revenue collectively reduced their workforces by more than 22,000 employees over the course of 2025.But to really put the latest layoff figures in context, we should compare them to previous first quarters. The 33 announcements in the first three months of 2026 are barely half of the 63 reports we saw in the same quarter of 2025, and significantly below the 57 and 58 rounds we listed in the first quarters of 2023 and 2024, respectively.In fact, we have to go back to the 30 layoff rounds reported in the first quarter of 2022 to find a similar level.The relative drop-off in layoff rounds that began in the final months of last year reflects the fact that many biopharmas have now conducted an overdue appraisal of their strategies, suggested Max Baumann, co-founder and Head of Execution at Treehill Partners, a healthcare-focused advisory firm.“During 2025, biotech and pharma started realizing things that they should have realized two or three years ago, which is: we need a course-correct,” Baumann told Fierce in an interview.“In early 2025, we saw panic, tariff fear, some clinical failures triggering individual layoffs at biotechs,” he added. “But within the larger pharma industry, we basically had a larger degree of uncertainty.” While some of this uncertainty may linger, there “just isn\'t as much meat left to cut” at larger companies, suggested Baumann, who pointed to Novo Nordisk’s decision in September to lay off 9,000 employees as well as Bayer’s long-running restructuring under CEO Bill Anderson.That’s not to paint too rosy a picture of the current state of the industry. In the final days of the first quarter, Takeda unveiled plans to cut 634 jobs in the U.S. as part of a massive restructuring designed to save the company more than 200 billion Japanese yen ($1.26 billion) annually. It followed the Japanese pharma’s announcement in January that it would remove 243 field-based commercial employees to prepare for the loss of exclusivity on its depression drug Trintellix.Other significant redundancy rounds included Germany’s Evotec—which will lay off 800 employees and shutter four sites over the next two years—and Viatris, which is shaving off around 10% of its 32,000-strong global workforce as part of plans to save up to $700 million annually. Among biotechs, some of the most severe layoffs were at Theravance Biopharma, which halved its headcount and abandoned its R&D ambitions in early March in the wake of a phase 3 fail for its blood pressure med.March also saw Gossamer Bio shrink its workforce by 48% after the company’s phase 3 study of seralutinib in patients with pulmonary arterial hypertension missed its primary endpoint. Meanwhile, Tessera Therapeutics unveiled plans at the start of the year to lay off 90 employees across a number of U.S. states despite the Flagship-founded company insisting it was “on the cusp of a critical inflection point” as it prepared its Regeneron-partnered in-vivo genome-editing product for the clinic.The quarter continued to see companies shutter, including IO Biotech, which followed its latest round of layoffs in January by filing for bankruptcy in March after its attempts to secure approval for its cancer vaccine ran out of road. Molecular glue company f5 Therapeutics also shut down in March, with the company’s CEO citing how “brutal” the past few years have been for early-stage biotechs. Another notable closure was Nido Biosciences, which decided to wind down after its small-molecule for a rare neurological disease disappointed in a phase 2 trial.While biopharma layoffs will remain a part of the life cycle of the industry, can we expect the relatively lower number of announcements to continue through the year?“I don\'t expect the same intensity to re-occur in 2026 from a general operations perspective,” Treehill Partners\' Baumann told Fierce.But there are the “wild cards” of the impact of AI and tariffs that could have unexpected impacts on the industry, he suggested.“Will that result in layoffs? I\'m not sure.”

武田制药又开始大规模裁员！这次预计有600多员工受影响，裁员期自2026年7月1日起至2027年12月31日止。 近日，武田制药向马萨诸塞州提交的《工人调整与再培训通知》(WARN)文件显示，其位于马萨诸塞州剑桥市的美国总部约634 个岗位受到影响，其中包括目前在该州的 247 个职位，以及其他州的 387 个职位。 本次裁员旨在优化资源配置，支持包括口服候选药物zasocitinib上市在内的重点投资。 近日，公司刚宣布了该药物III期斑块银屑病研究的积极数据：在III期随机、多中心、双盲、安慰剂和主动对照对照的Latitude PsO 3001和3002研究中，超过一半接受zasocitinib治疗的患者在第16周皮肤恢复清晰或接近清晰。公司计划于2026财年起向美国食品药品监督管理局及其他监管机构提交新药申请。为筹备这些新药上市，武田预计在未来几个月新增更多岗位。 这一举措也是武田制药自 3 月 25 日公布 12.6 亿美元的多年重组计划的头次披露大规模裁员情况。 据悉，受该计划影响，武田制药在截至 2025 年 3 月的财年中计入了 1280 亿日元(约合 8 亿美元)的重组费用，员工人数减少了 1800 多人(3.7%)。 据悉，在本次裁员之前，今年1月，武田制药也曾宣布在美国市场裁员243人，其此次调整主要涉及神经科学业务线相关岗位。而这次裁员的直接导火线，是一款名为Trintellix的抗抑郁药。这款年销售额超10亿美元的重磅药物，将在2026年失去美国市场独占权。仿制药一旦涌入，其价格将大幅暴跌，收入蒸发数十亿美元。 据武田制药相关人士表示，此次裁员是美国神经科学业务部门的“战略决策”，其核心目的包括应对Trintellix专利到期后即将到来的市场竞争；以及重新分配资源，为美国市场多款潜在新药的上市做准备。据悉，这些新药项目将创造超过400个新的商业领域岗位，以保障上市后的市场执行力。 资料显示，武田制药专注于肿瘤、罕见病、消化和神经科学四大核心治疗领域的药物研发，并在血液制品及疫苗领域进行研发投入，致力于为全球患者提供高度创新的药物和变革性的疗法。从业绩上看，2025财年第三季度公司累计收入为3,411.2亿日元，同比下降3.3%。核心营业利润下降3.4%至971.6亿日元，而报告的营业利润略增1.2%至422.4亿日元。 其实除了武田，今年以来，跨国药企裁员潮持续涌动。如晖致宣布最多减员10%，或将影响约3000名员工，预计将在未来三年内基本完成。默沙东也曾宣布，将裁减其美国北卡罗来纳州达勒姆市疫苗生产基地约150名员工，并停止该基地佳达修(Gardasil)系列HPV疫苗的生产。GSK宣布作为重组计划的一部分，计划削减研发岗位，预计将在美国和英国影响多达350个职位。 从行业层面看，裁员潮背后或是三大核心矛盾的集中爆发：一是专利悬崖集中到来，重磅药物到期，仿制药冲击导致营收下滑；二是研发投入高企，创新药研发周期长、成本高，药企需持续投入才能维持管线竞争力；三是市场竞争白热化，生物类似药、创新疗法不断涌现，传统药企市场被挤压。在此背景下，裁员成为药企 “降本增效、聚焦创新” 的直接手段。 参考：制药网 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通： 药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意